Neurochemical correlates of caudate atrophy in Huntington's disease

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 327-335

  Padowski, Jeannie M ^a,b   Weaver, Kurt E ^a   Richards, Todd L ^a   Laurino, Mercy Y ^a,c   Samii, Ali ^a   Aylward, Elizabeth H ^a,d   Conley, Kevin E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Caudate; Glutamate; Huntington's disease; Magnetic resonance imaging; Magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; WATER; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN FUNCTION; BRAIN REGION; BRAIN SIZE; CAG REPEAT; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; HUNTINGTON DISEASE GENE MUTATION CARRIER; LIMIT OF QUANTITATION; MALE; MIDDLE AGED; MOTOR PERFORMANCE; NEUROCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL PROCESSING; VOXEL BASED MORPHOMETRY; YOUNG ADULT; ANALOGS AND DERIVATIVES; ATROPHY; GENETICS; METABOLISM; MOTOR ACTIVITY; MUTATION; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ADULT; AGED; ASPARTIC ACID; ATROPHY; CAUDATE NUCLEUS; FEMALE; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR ACTIVITY; MUTATION; YOUNG ADULT;

EID: 84896141552     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25801     Document Type: Article

References (47)

1. [No authors listed] A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-983.
2. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006;66:1016-1020.
3. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82:405-410.
4. Henry PG, Mochel F. The search for sensitive biomarkers in presymptomatic Huntington disease. J Cereb Blood Flow Metab 2012;32:769-770.
5. Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull 2007;72(2-3):152-158.
6. Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 2000;74:2108-2119.
7. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 2010;75:1702-1710.
8. Gomez-Anson B, Alegret M, Munoz E, Sainz A, Monte GC, Tolosa E. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology 2007;68:906-910.
9. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999;53:806-812.
10. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord 1996;11:167-173.
11. van den Bogaard SJ, Dumas EM, Teeuwisse WM, et al. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J Neurol 2011;258:2230-2239.
12. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998;50:1033-1040.
13. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998;50:1357-1365.
14. Brief EE, Moll R, Li DK, Mackay AL. Absolute metabolite concentrations calibrated using the total water signal in brain (1)H MRS. NMR Biomed 2009;22:349-354.
15. Gasparovic C, Song T, Devier D, et al. Use of tissue water as a concentration reference for proton spectroscopic imaging. Magn Reson Med 2006;55:1219-1226.
16. Jansen JF, Backes WH, Nicolay K, Kooi ME. 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006;240:318-332.
17. Weaver KE, Richards TL, Liang O, Laurino MY, Samii A, Aylward EH. Longitudinal diffusion tensor imaging in Huntington's disease. Exp Neurol 2009;216:525-529.
18. Zhang Y, Long JD, Mills JA, Warner JH, Lu W, Paulsen JS. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011;156B:751-763.
19. Aylward EH, Rosenblatt A, Field K, et al. Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003;62:137-141.
20. Barta PE, Powers RE, Aylward E, et al. Quantitative MRI volume changes in late onset schizophrenia and Alzheimer's disease compared to normal controls. Psychiatry Res Neuroimaging 1997;68:65-75.
21. Schubert F, Gallinat J, Seifert F, Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004;21:1762-1771.
22. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
23. Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med 2004;51:904-912.
24. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-1238.
25. Kumar P, Kalonia H, Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep 2010;62:1-14.
26. Unschuld PG, Edden RA, Carass A, et al. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord 2012;27:895-902.
27. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
28. Clarke CE, Lowry M, Quarrell OW. No change in striatal glutamate in Huntington's disease measured by proton magnetic resonance spectroscopy. Parkinsonism Relay Disord 1998;4:123-127.
29. Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res 2005;1031:82-89.
30. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol 2000;21:659-665.
31. Joshi PR, Wu NP, Andre VM, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 2009;29:2414-2427.
32. Raymond LA, Andre VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011;198:252-273.
33. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 1991;11:1649-1659.
34. Hantraye P, Riche D, Maziere M, Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 1990;108:91-104.
35. Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002;125(pt 8):1908-1922.
36. Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009;34:78-86.
37. Miller BR, Dorner JL, Shou M, et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008;153:329-337.
38. Perry TL, Hansen S. What excitotoxin kills striatal neurons in Huntington's disease? Clues from neurochemical studies. Neurology 1990;40:20-24.
39. Reynolds GP, Pearson SJ. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci Lett 1987;78:233-238.
40. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science 1988;241:981-983.
41. Cepeda C, Hurst RS, Calvert CR, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003;23:961-969.
42. Graham RK, Pouladi MA, Joshi P, et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neuroscience 2009;29:2193-2204.
43. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010;90:905-981.
44. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease [serial online]. Cochrane Database Syst Rev 2009(3):CD006456.
45. Whittall KP, MacKay AL, Graeb DA, Nugent RA, Li DK, Paty DW. In vivo measurement of T2 distributions and water contents in normal human brain. Magn Reson Med 1997;37:34-43.
46. Whittall KP, MacKay AL, Li DK, Vavasour IM, Jones CK, Paty DW. Normal-appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T(2). Magn Reson Med 2002;47:403-408.
47. Wang CH, Willis DL, Loveland WD. Nuclear statistics. Radiotracer Methodology in the Biological, Environmental, and Physical Sciences. Englewood Cliffs, NJ: Prentice Hall; 1975:294-309.